throbber
13/308,658
`
`R
`
`Me 7 Pr—n
`s
`N
`H
`Me
`R
`'
`.1/“Nlo
`E
`
`S
`
`O
`
`WCH2
`
`
`
`RN
`
`CN
`
`3
`
`394726—95—5
`
`HCAPLUS
`
`3—Azabicyc1o[3.1.O]hexane—2—carboXamide,
`
`[2 0x0
`(4,4 dif1uorocyc1oheXy1)ac ty;] 6,6 dim thyl N [1
`2 amino 2
`[(2S)
`(1R,2S,5S)-
`(CA INDEX
`2-(2—propen-1-y1amino)ac tyl] 4 p nt n 1 y;]
`,
`NAML)
`
`Absolute stereochemistry.
`
`F
`
`F
`
`\ CH2
`
`\/\cH2
`
`[3
`
`S
`
`Me ::N H
`Me
`R
`"
`ll/N
`
`0
`
`RN
`
`CN
`
`3
`
`394727—13—0
`
`HCAPLUS
`
`3—Azabicyc1o[3.1.O]hexane—2—carboXamide,
`
`1 0X0 2
`[3,3 dim thyl
`[(3 ph ny1buty1)amino]buty1]
`6,6 dim thyl N [1
`fiX NAM*
`(CA IND
`- )
`oxo—2—(2—propen—1—y1amino)acety1]buty1]-
`
`[2
`
`131
`
`TEVA - EXHIBIT 1006 - PART 2 OF 2
`
`0260
`
`0260
`
`TEVA - EXHIBIT 1006 - PART 2 OF 2
`
`

`
`13/308,658
`
`Ph
`
`0 I
`
`NH— CH2— CH2— £H—Me
`O— H— Bu—t
`
`O
`
`O
`
`O
`H2C:CH—CH2—NH—fl—|é
`n—Pr—£H—NH—|é
`
`Me i N/
`
`Me
`
`RN
`
`CN
`
`3
`
`394727—l4—l
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboXamide,
`
`[(2 ph nyl thyl)amino]butyl]
`1 0X0 2
`[3,3 dim thyl
`6,6 dim thyl N
`*.X NAM*.)
`oxo—2—(2—propen—l—ylamino)acetyl]butyl]— (CA IND
`
`[1
`
`[2
`
`O
`
`O
`
`O
`H2C:CH—CH2—NH—g—|é
`n-Pr—$H—NH—E
`
`Me i N/
`
`Me
`
`O NH—CH2—CH2—Ph
`|J— £H— Bu-t
`
`RN
`
`CN
`
`394727—l5—2
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboXamide,
`
`3—[2—[(3,3—dimethylbutyl)amino]-3,3—dimethyl—l—oxobutyl]-6,6—dimethyl—N—[l—
`(CA IND*.X NAM*.)
`[2—oxo—2—(2—propen—l—ylamino)acetyl]butyl]-
`
`O
`
`O
`
`O
`H2C==CH—CH2—NH—fl—g
`n_Pr_£H_NH_E
`
`O NH—CH2—CH2—CMe3
`
`Me
`
`Me
`
`F N/MH_Bu_t
`
`RN
`
`CN
`
`394727—l8—5
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboXamide,
`3
`[(2S)
`2 amino 3,3 dim thyl
`l oxobutyl]—N—[1-[2-(3—buten—l—ylamino)—2—
`(CA IND *.X NAM *-)
`(lR,2S,5S)-
`oxoac tyl] 4 p nt n l yl] 6,6 dim thyl
`,
`
`Absolute stereochemistry.
`
`132
`
`0261
`
`0261
`
`

`
`13/308,658
`
`S
`
`Me
`
`Me
`
`>< I
`R
`
`N
`S|
`
`O
`H
`- {N
`
`0
`
`394727-36-7
`
`HCAPLUS
`
`RN
`CN
`
`M
`
`e
`
`Me
`
`RN
`CN
`
`3—Azabicyclo[3.l.O]hexane—2—carboXamide,
`N-[l—[2—(3—buten—l—ylamino)
`2 oxoac tyl] 4 p nt n 1 yl]
`[[[[(lR,4S)-7,7-dime
`:hyl—2—oXobicyclo[2.2.l]hept—l—
`yl]methyl]sulfonyl]am1no]-3,3—dimethyl—l—oXobutyl]-6,6—dimethyl—,
`(CA IND.
`*-)
`(lR,2S,5S)-
`
`3
`
`[(28)
`
`2
`
`N__
`
`C— NH— CH— CH2— CH2— CH1 CH2
`
`IA
`
`II
`
`O
`
`II
`
`— C— NH— CH2— CH2— CH: CH2
`O
`
`394727-38-9
`
`HCAPLUS
`
`3—Azabicyc;o[3.l.O]hexane—2—carboXamide,
`2
`[(2S)
`3
`N-[l-[2-(3-buten-1-ylamino)
`2 oxoac tyl] 4 p nt n 1 yl]
`[[(dimethy'amino)su1fony1Jamino]-3,3—dimethyl—l—oXobutyl]-6,6—dimethyl—,
`(lR,2S,5S)-
`(CA IND*.X NAM~.)
`
`Absolute stereochemistry.
`
`133
`
`0262
`
`0262
`
`

`
`13/308,658
`
`RN
`
`395649-30-6
`
`HCAPLUS
`
`Glycinamide,
`CN
`(28) 6,6 dim thyl 3
`(28)—2—cyclohexyl—N—(3—methylbutyl)glycyl
`azabicyclo[3.l.0]hexane—2—carbonyl—3—amino—2—oxohexanoylglycyl—N,N-
`dimethyl-2-phenyl-,
`(2S)-
`(9CI)
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`Me2CH/\/
`
`5
`
`N
`
`RN
`
`CN
`
`395649-34-O HCAPLUS
`
`(28) 6,6 dim thy; 3
`Glycinamide, 3-methyl-N-(3-phenylbutyl)Valyl
`azabicyclo[3.l.0]hexane—2—carbonyl—3—amino—2—oxohexanoylglycy;—N,N-
`dimethyl-2-phenyl-,
`(2S)-
`(9CI)
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`134
`
`0263
`
`0263
`
`

`
`13/308,658
`
`Me
`Me
`
`>*<:|
`
`fi MePh
`t—BL1
`N;;l;:O
`H
`_
`sl
`0
`. ji/,N
`Pr n
`H
`0
`N\\v/,fl\\
`
`O
`
`0
`
`Ph
`S
`
`N
`H
`
`NMe2
`
`O
`
`RN
`
`CN
`
`395649-35-l
`
`HCAPLUS
`
`(28) 6,6 dim thy; 3
`3 m thyl N (2 ph nyl thyl)Valyl
`Glycinamid ,
`azabicyclo[3.l.0]hexane—2—carbonyl—3—amino—2—oxohexanoylglycy;—N,N-
`dimethyl-2-phenyl-,
`(2S)-
`(9CI)
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`Bu-t
`
`HN
`
`Me
`
`Me
`
`RN
`
`CN
`
`Ph//-‘/// ;;1;;
`N
`><:
`I
`|
`
`,
`
`S
`
`*T”
`I
`o
`
`O
`H
`N
`
`Pr-
`
`H
`
`H
`N
`
`0
`
`0
`
`Ph
`S
`
`N
`H
`
`NMe2
`
`o
`
`395649—36—2
`
`HCAPLUS
`
`(28) 6,6 dim thyl 3
`Glycinamide, N—(3,3—dimethylbutyl)—3—methylvalyl
`azabicyclo[3.l.0]hexane—2—carbonyl—3—amino—2—oxohexanoylglycyl—N,N-
`dimethyl-2-phenyl-,
`(2S)-
`(9CI)
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`135
`
`0264
`
`0264
`
`

`
`13/308,658
`
`RN
`
`CN
`
`395652—00—3
`
`HCAPLUS
`
`3—Azabicyclo[3.1.O]hexane—2—carboXamide,
`
`[2 oxo 2
`3-[(2S)-2-amino-2-cycloh Xylac tyl] 6,6 dim thyl N [1
`ylamino)ac tyl] 4 p nt n 1 yl]
`,
`(2S)-
`(CA IND«X NAM«)
`
`(2 prop n 1
`
`Absolute stereochemistry.
`
`IT
`
`3§é?35~§§~??
`
`3§$?3S~§§w§P
`
`IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic
`RL:
`preparation); PREP (Preparation); RACT (Reactant or reagent)
`(preparation of peptides as NS3—serine protease inhibitors of hepatitis
`
`RN
`
`CN
`
`virus)
`394735-46-7
`
`HCAPLUS
`
`Glycinamide, 3-methyl-L-Valyl-(1R,2S,5S)-6,6-dimethyl-3-
`
`azabicyclo[3.1.0]hexane—2—carbonyl—B—amino—a—
`oxocyclopropanebutanoylglycy; N,N dim thyl 2 ph nyl
`(2S)-
`(CA IND*.X NAM*.)
`
`, monohydrochloride,
`
`Absolute stereochemistry.
`
`136
`
`0265
`
`0265
`
`

`
`H2N;;i;;Bu—t
`
`13/308,658
`
`0
`
`fi\\V//fl\\
`
`Ph
`
`N
`H
`
`S
`
`NMe2
`
`O
`
`O
`
`O HCl
`
`O
`§
`
`Me
`
`Me
`
`S
`
`R
`
`N
`S
`
`‘
`
`.
`
`1
`
`RN
`
`CN
`
`394735—49—O HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboXamide,
`[(2S)
`3
`N-[3-amino-l-(cyclopropylmethyl)-2,3-dioxopropyl]
`dimethyl—l—oxobutyl]—6,6—dimethyl—, hydrochloride (l:l),
`IND«X NAME)
`
`2 amino 3,3
`(lR,2S,5S)— (CA
`
`Absolute stereochemistry.
`
`O HCl
`
`OS.CITING REF COUNT:
`
`35
`
`T{«Rn ARE 35 CAPLUS RECORDS THAT CITE THIS
`RECORD (40 CITINGS)
`
`ANSWER 77 OF 87
`L49
`ACCESSION NU RER:
`DOCJ ENT NUMR?%:
`
`CORYRIGHT 20l2 ACS on STN
`HCARLUS
`2000:790l73
`HCAPLUS Full~text
`l33:350506
`
`TIT.?:
`
`INVENTOR(S):
`
`PATENT ASSIGN««(S).
`SOUQCE:
`
`?repara:ion of 2,3—methano—amino acid derivatives as
`anticoagulant agents
`De Nanteuil, Guillaume; Gloanec, Philippe; Verbeuren,
`Tony; Ripin, Alain
`Adir et Compagnie, Fr.
`Eur. Pa:. Appl., 34 pp.
`CODEN:
`nPXXDW
`
`137
`
`0266
`
`0266
`
`

`
`13/308,658
`
`DOCJMENT TYPE:
`LANGUAGE:
`FAMILY ACC. MUM. COUNT:
`PATENT INFOR.ATION:
`
`Patent
`French
`1
`
`?ATENT NO.
`
`KIND
`
`DATE
`
`APPLICATION NO.
`
`DATE
`
`EP 2000-401197
`
`20000502 <—-
`
`IT, LI, LU, NL, SE, MC, PT,
`
`19990503 <—-
`
`20000428 <—-
`20000430 <—-
`
`20000502 <—-
`20000502 <—-
`20000502 <—-
`
`20000502 <—-
`20000502 <—-
`20000502 <—-
`20000502 <—-
`20000502 <—-
`20000503 <—-
`
`20000503 <—-
`20000503 <—-
`
`20000503 <—-
`20000508 <—-
`
`20010423 <—-
`19990503 <—-
`
`20001108
`A1
`3? 1050531
`20011205
`31
`E? 1050534
`R:
`AT, 3E, CH, DE, DK, ES, FR, G3, GR,
`IE, SI, LT, LV, FI,
`30
`FR 2793248
`A1
`20001110
`FR 2793248
`31
`20010629
`?L 198571
`31
`20080630
`CN 1277961
`A
`20001227
`CN 1130347
`C
`20031210
`NO 2000002314
`A
`20001106
`VZ 504298
`A
`20010126
`{J 2000001712
`A2
`20010328
`{J 2000001712
`A3
`20020228
`JS 6288077
`31
`20010911
`AP 210131
`T
`20011215
`X 2000004241
`A
`20020308
`I‘1050534
`3
`20020531
`ES 2169716
`T3
`20020716
`CA.2308780
`A1
`20001103
`CA 2308780
`C
`20030422
`ZA.2000002152
`A
`20001107
`AU 2000031325
`A
`20001130
`AU 763670
`32
`20030731
`3R.2000002075
`A
`20010102
`JP 2000344745
`A
`20001212
`JP 3200053
`32
`20010820
`{K 2001-102869
`{K 1032237
`A1
`20040511
`A
`FR.l999-5601
`INFO.:
`?RIORITY APPLN.
`ASSIGNMENT {ISTORY FOR US ?ATENT AVAILA3LE IN LSUS DISPLAY FORMAT
`
`FR.1999-5601
`
`PL 2000-339967
`CN 2000-119227
`
`V0 2000-2314
`NZ 2000-504298
`{U 2000-1712
`
`JS 2000-561618
`A? 2000-401197
`X 2000-4241
`3? 2000-401197
`38 2000-401197
`CA.2000-2308780
`
`ZA.2000-2152
`AU 2000-31325
`
`3R.2000-2075
`JP 2000-134144
`
`OTHER SOURCE(S):
`«D
`~n:ered SUN:
`G1
`
`MARPAT l33:350506
`10 Nov 2000
`
`[X = (CH2)n; n==2, 3; R1 = cycloalkyl; R2 = amino, alkyl,
`I
`Amino acid.deriVs.
`OH, guanidinoisothiourido; Ar==ary1, heteroaryl; X1==OH, substituted.amine]
`Thus,
`were prepared as anticoagulants.
`1-(N-carboXymethyl-(2R)-3-cycloheXylalanyl)-N-(4-amidinobenzyl)-(2S,3R)-
`
`138
`
`0267
`
`0267
`
`

`
`13/308,658
`
`IT
`
`RN
`CN
`
`2,3—methanoprolinamide hydrochloride was prepared and tested for its
`anticoagulant activity (IC5O = 5.3 uM).
`3{
`"1Q~1$“5§
`
`RR: SAC (?iological activity or effector, except adverse); RSU (Riological
`study, unclassified); RCT (Reactant); SPN (Syn:hetic preparation); THU
`(Therapeutic use); SIOL (?iological study); PREP (Preparation); RACT
`(Reactant or reagen:); USES (Uses)
`(preparation of 2,3—methano—amino acid derivs. as anticoagulant agents)
`3049l0—l6—5
`HCAPLUS
`
`2—Azabicyclo[3.l.0]hexane—l—carboxamide,
`2—[(2R)-2—amino—3—cyclohexyl—l—oxopropyl]—N—[[4-
`(aminoiminomethyl)phenyl]methyl]-, hydrochloride
`IND«X NAM«)
`
`(1:2),
`
`(lS,5R)-
`
`(CA
`
`Absolute stereochemistry.
`
`
`
`?AC('
`activity or effector, except adverse); SSU (?iological
`Aiological
`study, unclassified); SPN (Synthetic preparation); THU (Therapeitic use);
`SIOL (Siological study); PREP (Preparation); USES (Uses)
`(oreparation of 2,3—methano—amino acid derivs. as anticoagulant agents)
`3049l0—l7—6
`HCAPLUS
`
`RN
`
`CN Glycine, N—[(lR)—2—[(lS,5R)—l—[[[[4—
`
`(aminoiminomethyl)phenyl]methyl]amino]carbonyl]—2—azabicyclo[3.l.0]hex—2—
`yl]—l-(cycloh Xylm thyl)
`2 oxo thyl]
`, hydrochloride (9CI)
`(CA INDEX
`NAME)
`
`Absolute stereochemistry.
`
`139
`
`0268
`
`0268
`
`

`
`13/308,658
`
` H2N
`
`NH
`
`"x HCl
`
`RN
`
`CN
`
`304910—19—8
`
`HCAPLUS
`
`2—Azabicyclo[3.1.0]heXane—1—carboxamide,
`]
`2
`N-[[4-(amihoimihomethyl)ph hyl]m thy;
`]—I
`[[(phehylmethyl)sulfohyl]amiho]propyl
`(CA IND nX NAM fl)
`
`Absolute stereochemistry.
`
`[(2R)
`1 oxo 3 ph nyl 2
`(1:1),
`(1S,5R)
`hydrochloride
`
` Ph
`
`.’HCl
`
`H2N
`
`NH
`
`RN
`
`3o491o—2o—1
`
`HCAPLUS
`
`CN Glycine, N-[(1R)—2—[(1S,5R)—1—[[[[4-
`
`(amihoimihomethyl)phehyI_]methyl]amino]carbonyl]—2—azabicyclo[3.1.0]hex—2—
`(CA IND nX NAM.
`yl]
`2 oxo 1
`(ph hy:_m thyl)
`thyl]
`, hydrochloride (9CI)
`
`Absolute stereochemistry.
`
`140
`
`0269
`
`0269
`
`

`
`13/308,658
`
`H2N
`
`NH
`
`.x HCl
`
`RN
`
`CN
`
`304910—21—2
`
`HCAPLUS
`
`2—Azabicyclo[3.1.0]heXane—1—carboxamide,
`2 amino 1 oxo 3,3
`[(2R)
`N-[[4-(amihoimihomethyl)ph hyl]m thyl] 2
`diphenylpropyl]-, hydrochloride (1:2),
`(1S,5R)— (CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`H2N
`
`NH
`
`02 HCl
`
`RN
`
`CN
`
`2
`
`304910—22—3
`
`HCAPLUS
`
`2—Azabicyclo[3.1.0]heXane—1—carboxamide,
`
`2 amino 1 oxo 3,3 diph nylpropyl]-N-[(6-amino-3-pyridihyl)methyl]-
`[(2R)
`, hydrochloride (1:2),
`(1S,5R)-
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`141
`
`0270
`
`0270
`
`

`
`13/308,658
`
`
`
`RN
`
`CN
`
`3049l0—23—4
`
`HCAPLUS
`
`2—Azabicyclo[3.l.0]heXane—l—carboxamide,
`2—[(2R)—2—amino—3,3—dicyclohexyl—l—oxopropyl]—N—[[4-
`(amihoimihomethyl)phehyl]methyl]-, hydrochloride (1:2),
`IND«X NAM«)
`
`(lS,5R)-
`
`(CA
`
`Absolute stereochemistry.
`
`H2N
`
`NH
`
`N
`
`R
`
`g
`
`0
`
`02 HCl
`
`RN
`
`3049l0—24—5
`
`HCAPLUS
`
`CN Glycine, N—[(lR)—2—[(lS,5R)—l—[[[[4—
`
`(aminoiminomethyl)pheny;]methyl]amino]carbonyl]—2—azabicyclo[3.l.0]hex—2—
`yl]-l-(dicycloh Xylm thyl)
`2 oxo thyl]
`, hydrochloride (9CI)
`(CA INDEX
`NAME)
`
`Absolute stereochemistry.
`
`142
`
`0271
`
`0271
`
`

`
`13/308,658
`
`CO2H
`
`NH
`
`"x HCl
`
`RN
`CN
`
`3049l0—26—7
`
`HCAPLUS
`
`2—Azabicyclo[3.l.0]hexane—l—carboxamide,
`]
`2
`N-[[4-(amihoimihomethyl)ph hyl]m thy;
`]—I
`[[(phenylmethyl)sulfonyl]amino]acety;
`nX NAM fl
`(CA IND
`
`Absolute stereochemistry.
`
`[(2R)
`2 cyclohexyl—2—
`(l:l
`),
`hydrochloride
`
`(lS,5R)—
`
`
`
`NH
`
`CFHC1
`
`RN
`CN
`
`3o4910—27—8
`
`HCAPLUS
`
`Glycine, N-[(lR)—2—[(lS,5R)—l—[[[[4-
`
`(aminoiminomethyl)phenyl]methyl]amino]carbonyl]—2—azabicyclo[3.l.0]hex—2—
`nX NAM fl)
`(9CI)
`(CA IND
`yl]—l—cyclohexyl—2—oXoethyl]—,
`hydrochloride
`
`Absolute stereochemistry.
`
`143
`
`0272
`
`0272
`
`

`
`13/308,658
`
`H2N
`
`NH
`
`
`
`.B< HCl
`
`RN
`
`304910-28-9
`
`HCAPLUS
`
`CN G;ycine, N-[(lR)-2-[(lS,5R)-l-[[[[4-
`
`_o[3.l.O]heX—2—
`(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-2-azabicyci
`dihydroch;oride (9CI)
`(CA
`y;]-1-cycloh Xyl 2 0X0 thyl]
`,
`thyl
`st r,
`IND«X NAM«)
`
`Absolute stereochemistry.
`
`EtO
`
`WA“
`0
`.
`
`
`
`02 HCl
`
`H2N
`
`NH
`
`RN
`
`3049l0—29—0
`
`HCAPLUS
`
`CN G;ycine, N—[(lR)—l—[[(lS,5R)—l—[[[[4—
`
`_]amino]carbonyl]—2—azabicyclo[3.l.0]hex—2—
`(aminoiminomethyl)phenyl]methyI
`(CA IND nX NAM fl)
`]—I dihydrochloride (9CI)
`y;]carbonyl]—3—methylbuty;
`
`Absolute stereochemistry.
`
`144
`
`0273
`
`0273
`
`

`
`13/308,658
`
`H2N
`
`NH
`
`02 HCl
`
`RN
`
`CN
`
`3049lO—7l—2
`
`HCAPLUS
`
`2—Azabicyclo[3.l.0]heXane—l—carboxamide,
`[(2R)
`N-[[4-(aminoiminomethyl)ph nyl]m thyl] 2
`diphenylpropyl]-,
`(lS,5R)-
`(CA IND«X NAM«)
`
`2 amino 1 0X0 3,3
`
`Absolute stereochemistry.
`
`H2N
`
`NH
`
`RN
`
`304910-72-3
`
`HCAPLUS
`
`CN G;ycine, N-[(lR)-2-[(lS,5R)-l-[[[[4-
`
`(aminoiminomethyl)phenyl]methyl]amino]carbonyl]—2—azabicyclo[3.l.0]hex—2—
`y;]-1-cyclohexyl-2-oxoethyl]-
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`145
`
`0274
`
`0274
`
`

`
`13/308,658
`
`
`
`NH
`
`IT
`
`3Q§91§~E5~S
`
`RL: RCT (Reactant); RACT (Reactant or reagent)
`(preparation of 2,3—methano—amino acid derivs. as anticoagulant agents)
`3049l0—25—6
`HCAPLUS
`
`2—Azabicyclo[3.l.0]heXane—l—carboxamide,
`
`RN
`
`CN
`
`2—[(2R)-2-amino-2-cyclohexylacetyl]-N-[[4-(aminoiminomethyl)phenyl]methyl]-
`, hydrochloride (1:2),
`(lS,5R)-
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`H2N
`
`NH
`
`02 HCl
`
`IT
`
`3G§§1§~1L~§F
`
`3Q§§1G
`
`A1.»
`
`31w
`.~.t'
`~
`
`RN
`
`CN
`
`RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
`(Reactant or reagent)
`(preparation of 2,3—methano—amino acid derivs. as anticoagulant agents)
`3049l0—l5—4
`HCAPLUS
`
`2—Azabicyclo[3.l.0]heXane—l—carboxamide,
`2—[(2R)-2-amino-3-cycloheXyl-l-oxopropyl] N [(6 amino 2 m :hyl 3
`pyridinyl)methyl]-, hydrochloride (l:2),
`(lS,5R)-
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`146
`
`0275
`
`0275
`
`

`
`13/308,658
`
`Me
`
`N/
`H2N \
`
`l
`
`
`
`O2 HCl
`
`RN
`CN
`
`304910-18-7
`
`HCAPLUS
`
`2—Azabicyclo[3.1.0]hexane—1—carboxamide,
`[(2R)
`N-[[4—(aminoiminomethyl)ph nyl]m thyl] 2
`phenylpropyl]-, hydrochloride (1:2),
`(1S,5R)-
`
`2 amino 1 oxo 3
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`H2N
`
`NH
`
`Ph
`
`
`
`02 HCl
`
`R*.J:*R*.NC*. COUNT:
`
`2
`
`T-I*.R*. AR*. 2 CIT*.D R*.J:*.R*.NC*.S AVAIT.A'3T.'?‘. FOR THIS
`RECORD. ALL CITATIONS AVAIT.A'3T.'3‘.
`IN TH*. R4.
`J:ORlVlAT
`
`ANSWER 78 OF 87
`L49
`ACCESSION \IU '3'7‘.R:
`DOCJ ENT VJMR?R:
`
`CORYRIGHT 2012 ACS on STN
`HCAPLUS
`l99l:506007
`HCAPLUS Full---text
`115:106007
`
`ORIGIVAL %«b«R«NC« NO.:
`TIT.?:
`
`INVEWTOR(S):
`
`PATEVT ASSIGN««(S)
`SOUQCE:
`
`115:17985a,17988a
`Treatment of cardiac and vascular hypertrophy and
`hyperplasia with angiotensin-converting enzyme
`inhibitors
`
`Linz, Wolfgang; Schoelkens, 3ernward; Scholz,
`Wolfgang; Wiemer, Gabriele; Jrbach, Hans Joerg;
`Henning, Rainer; Teetz, Volker
`Hoechst A.—G., Germany
`Ger. Offen.,
`12 pp.
`
`147
`
`0276
`
`0276
`
`

`
`13/308,658
`
`DOCJMENT TYPE:
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`PATENT INFOR.ATION:
`
`CODEN: GWXXBX
`Patent
`German
`I
`
`?ATENT NO.
`
`KIND
`
`DATE
`
`APPLICATION NO.
`
`DATE
`
`33 1989-3926606
`3? 1990-115230
`
`19890811
`19900808
`
`NO 1990-3532
`
`19900810
`
`AU 1990-60920
`
`19900810
`
`HU 1990-4966
`
`19900810
`
`19910214
`A1
`33 3926606
`19910320
`A1
`3? 117473
`19930915
`31
`3? 417473
`IT, LI, LU, NL, SE
`R:
`AT, 3E, CH, DE, DK, ES, FR, G3, GR,
`AT 94409
`T
`19931015
`AT 1990-115230
`19900808
`38 2059931
`T3
`19941116
`38 1990-115230
`19900808
`DD 297063
`A5
`19920102
`DD 1990-343366
`19900809
`JS 5231083
`A
`19930727
`JS 1990-564618
`19900809
`IL 95327
`A
`19951031
`IL 1990-95327
`19900809
`CA.2023089
`A1
`19910212
`CA 1990-2023089
`19900810
`CA 2023089
`C
`20030114
`NO 9003532
`A
`19910212
`NO 306979
`31
`20000124
`AU 9060920
`A
`19910214
`AU 631914
`32
`19921210
`HU 54504
`A2
`19910328
`HU 205008
`3
`19920330
`JP 03083957
`A
`19910409
`JP 3452199
`32
`20030929
`ZA 9006327
`A
`19910529
`CS 277644
`36
`19930317
`KR.185969
`31
`19990501
`PRIORITY APPLN.
`
`INFO.:
`
`JP 1990-210564
`
`19900810
`
`ZA 1990-6327
`CS 1990-3958
`KR 1990-12267
`DE L989-3926606
`EP 1990-115230
`
`19900810
`19900810
`19900810
`A L98908Ll
`A
`19900808
`
`<__
`ASSIGNMENT {ISTORY FOR US PATENT AVAILA3LE I\ LSUS DISPLAY FORMAT
`
`OTHER SOURCE(S)'
`«D
`n:ered SUN
`GI
`
`MARPAT ll5:lO6007
`23 Sep 1991
`
`OV OEt
`-
`<:Y HN
`
`COZH
`
`N
`
`Me
`
`Ph
`
`The angiotensin-converging enzyme inhibitors
`R(CH2)nCH(CO2R2)NHCHRlCONR5CHR4CO2Rl
`(R==H, a1iphatic radical, ary1, etc.;
`Rl
`H, a1iphatic radica1, aryl, heterocyclyl, etc.; R2, R3 = H, aliphatic
`148
`
`0277
`
`0277
`
`

`
`13/308,658
`
`radical, alicyclic radical,
`aryl, etc.; R4, R5 together with the carrier
`atoms are heterocyclyl; n = 1, 2) are drugs for the treatment of cardiac and
`Vascular hypertrophy and hyperplasia,
`in newborns. Oral administration of
`tablets containing N (1 S carb toxy 3 ph nylpropyl)—S—alanyl—
`
`cis—endo—2—azabicyclo[3.3.0]octane-3,S—carboXylic acid H.or 10 ug/kg/day,
`for 3 wk) normalized the weight and wall thickness in the heart of rats with
`exptl. cardiac hypertrophy,
`induced by stricture of the abdominal aorta.
`.NwNn
`.“ A
`Formulation examples are given.
`3&sb;~$s~a
`
`RR: 310% (3iological study)
`(cardiac and vascular hypertrophy and hyperplasia treatment by)
`9978l—97—2
`HCAPLUS
`
`2—Azabicyclo[3.1.0]heXane—3—carboxylic acid,
`2—[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-,
`
`[1S—[1d,2[R*(R*)],3B,5a]]— (9CI)
`
`(CA IND«X NAM«)
`
`IT
`
`RN
`CN
`
`Absolute stereochemistry.
`
`OEt
`
`O
`V
`-
`
`CO2H
`
` ( HNM Ph
`N—~\“//%\Me
`
`S
`
`O
`
`OS.CITING REF COUNT:
`
`2
`
`THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
`(2 CITINGS)
`
`L49
`
`ANSWER 79 OF 87
`
`HCAPLUS
`
`COPYRIGHT 20l2 ACS on STN
`
`ACCESSION VU RER:
`DOC
`ENT VJMRER:
`
`1991 450274
`ll5:50274
`
`HCAPLUS
`
`~
`§_
`
`
`ORIGIWAL %«t«R«NC« NO.:
`TIT E:
`
`AUT{OR(S):
`
`COR?O%ATE SOURCE:
`SOUQCE:
`
`DOCJMENT TYPE:
`
`EANGUAGE:
`«D
`«n:ered STN:
`GI
`
`115:8757a,8760a
`Synthesis and conformational analysis of
`L—aspartylproline and L—aspartyl—2,3—methanoproline
`propyl esters
`Matsui, S.; Srivastava, V. P.; Holt, 3. M.; Taylor, 3.
`W.; Stammer, C. H.
`Sch. Chem. Sci., Univ. Georgia, Athens, GA, 30602, USA
`International Journal of Peptide & Protein Research
`(1§§1), 37(4), 306-14
`CODEN:
`IJPPC3;
`ISSN: 0367-8377
`Journal
`
`English
`10 Aug 1991
`
`149
`
`0278
`
`0278
`
`

`
`13/308,658
`
`H—L—AspN
`CO2Pr
`
`H2)n
`
`I
`
`E/Q
`N
`CO2R
`CO2CH2Ph
`
`II
`
`A3
`
`IT
`
`RN
`
`CN
`
`(n.= l, 0) were prepared
`) diast r om rs of the title compds. I
`and (
`(i)
`Th
`and their conformations were studied Via crystal structure, NMR, and mol.
`mechanics.
`The (+)— and (—)—isomers of 2,3—methanoproline II (R = H) were
`obtained from (i)—II
`(R.= CMe3) Via resolution of (i)—II
`(R.= H). All solid
`dipeptides had a bitter taste with no indication of sweetness.
`13$” §~§$~§§
`13
`~$G~3§
`
`RL: SPN (Synthetic preparation); PREP (Preparation)
`(preparation, conformation, and :aste of)
`134666-90-3
`HCAPLUS
`
`2—Azabicyclo[3.l.0]hexane—2—butanoic acid,
`
`B—amino—y—oxo—l—(propoxycarbonyl)—,
`[lS-[la,2(R*),5a]]- (9CI)
`(CA INDnX NAM«)
`
`Absolute stereochemistry.
`
`CO2H
`
`n—PrO
`
`RN
`
`CN
`
`l34732—59—5
`
`HCAPLUS
`
`2—Azabicyclo[3.l.0]hexane—2—butanoic acid,
`
`B—amino—y—oxo—l—(propoxycarbonyl)—,
`[lR—[ld,2(S*),5d]]— (9CI)
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`NH2
`
`0
`
`CO2H
`
`n—PrO
`
`150
`
`0279
`
`0279
`
`

`
`13/308,658
`
`OS.CITING REF COUNT:
`
`3
`
`THnRn ARn 3 CAPLUS RECORDS THAT CITE THIS RECORD
`(3 CITINGS)
`
`ANSWER 80 OF 87
`L49
`ACCESSION NU 3ER:
`DOCJ ENT NJM3?%:
`
`COPYRIGHT 2012 ACS on STN
`HCAPLUS
`l988:5l6052
`HCAPLUS
`R
`”
`
`109:116052
`
`ORIGINAL %ntn%nNCfi NO.:
`TIT.?-
`
`INVENTOR(S):
`PATENT ASSIGNnn(S):
`SOUQCE:
`
`DOCJMENT TYPE:
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`PATENT INFOR.ATION:
`
`lO9:l924la,l9244a
`Nootropic pharmaceutical containing
`angiot nsin conv rting nzym inhibitors (ACE
`inhibitors) and their use for the treatment of
`cognitive dysfunction
`Hoc<, Franz; Scholtholt, Josef
`Hoechst A.-G., Fed. Rep. Ger.
`Ger. Offen., 15 pp.
`CODEN: GWXXBX
`Patent
`German
`1
`
`?ATENT NO.
`
`KIND
`
`DATE
`
`APPLICATION NO.
`
`DATE
`
`A1
`33 3610391
`A2
`3? 243645
`A3
`3? 243645
`31
`3? 243645
`R:
`AT, 3E, CH, Dn, nS,
`AT 102954
`T
`ES 2061447
`T3
`FI 8701304
`A
`Fl 91876
`3
`Fl 91876
`C
`PU 46046
`A2
`PU 203117
`3
`DD 280765
`A5
`EU 202118
`3
`DK 8701535
`A
`DK 172221
`31
`KO 8701282
`A
`KO 178546
`3
`KO 178546
`C
`AU 8770649
`A
`AU 621278
`32
`JP 62240698
`A
`ZA 8702230
`A
`SU 1836335
`A3
`CA.1341064
`C
`CN 87102304
`A
`CN 1031267
`C
`CS 276179
`36
`CS 276385
`36
`
`19871008
`19871104
`19900124
`19940316
`tR, G3, GR,
`19940415
`19941216
`19870928
`19940513
`19940825
`19880928
`19910528
`19900718
`19910228
`19870928
`19980112
`19870928
`19960108
`19960417
`19871001
`19920312
`19871021
`19871028
`19930823
`20000801
`19871230
`19960313
`19920415
`19920513
`
`33 1986-3610391
`3? 1987-103938
`
`19860327
`19870318
`
`IT, LI, LU, NL, SE
`AT 1987-103938
`ES 1987-103938
`FI 1987-1304
`
`19870318
`19870318
`19870325
`
`HU 1987-1308
`
`19870325
`
`DD 1987-301118
`HU 1989-6609
`DK 1987-1535
`
`19870325
`19870325
`19870326
`
`NO 1987-1282
`
`19870326
`
`AU 1987-70649
`
`19870326
`
`JP 1987-70541
`ZA 1987-2230
`SU 1987-4202302
`CA 1987-533092
`CN 1987-102304
`
`CS 1987-2126
`CS 1989-6519
`
`19870326
`19870326
`19870326
`19870326
`19870327
`
`19870327
`19870327
`
`0280
`
`0280
`
`

`
`13/308,658
`
`US 1991—711719
`DE 1986-3610391
`EP 1987-103938
`
`19910607 <——
`19860327 <——
`19870318
`
`A
`A
`
`31 19870325 <——
`-8 1987-29905
`31 19880801 <——
`-8 1988-226521
`33 19890606 <——
`OS 1989-362288
`I\
`LSUS DISPLAY FORMAT
`
`US 5231084
`PRIORITY APPLN.
`
`INFO.:
`
`A
`
`19930727
`
`<__
`
`ASSIGNMENT {ISTORY FOR US PATENT AVAILARLR
`
`OTHER SOURCE(S):
`«D
`«n:ered STN:
`GI
`
`MARPAT 109:116052
`01 Oct 1988
`
`R3OOC— CH—N—C—CH—NH— CH— (CH2)n—R
`$4
`$5 o
`$1
`cooR2
`
`C3-9
`
`ACE inhibitors (1; R = H,
`optionally substituted C1—8 aliphatic,
`I
`C7-14 araliph.,
`C7—14 aliphatic—alicyclic
`a'icyc'ic, C6—12 aromatic
`hydrocarbyl, SR6, OR6; R1 = H, optionally substituted C1
`-6 aliphatic, c3—9
`
`a icyc'ic ,'
`C4—13 alicyclic—aliphatic , aryl,
`C7—16 araliph. hydrocarbyl,
`C5—12 heteroaryl or protected.amino acid side chain; R2, R3 = C1—6 aliphatic
`, C3-9 alicyclic, C6—12 aromatic, C7—16 araliph. hydrocarbyl; CNR4R5==C3—15
`C5—12 aromatic
`mono-, bi—,
`tricyclic heterocyci
`_yl; R6 —
`C1-4 aliphatic ,
`n
`1, 2)
`hydrocarby;
`,
`C5—12 heteroaryl;
`or their salts are nootropic
`_es contained
`pharmaceuticals.
`Gelatin capsul
`1'
`[N (1 S
`carb thoxy 3 ph nyi
`_propyl)-S-alanyl]-(3'S,5'S)-
`Mg
`spirobicyclo[2.2.2]octane—2,3'—pyrrolidin—5'—ylcarboxylic acid 10,
`stearate 1,
`and lactose 214 mg.
`The nootropic efficacy
`of I was tested by
`:he s
`the inhibitory passive avoidance test in mice using
`:ep—through model.
`nD (M nD) of 1.0-30 mg/kg
`Scopolamine—induced.amnesia.was reVersed.witha1min.
`M
`whereas for Piracetam,
`N11”.
`,1 N
`orally in mice,
`ED was 500-1000 mg/kg.
`$3s§1~$;wA
`
`RR: 310% (3iological study)
`(nootrooic drug)
`99781—97—2
`HCAPLUS
`
`2—Azabicyclo[3.1.0]heXane—3—carboxylic acid,
`2—[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-,
`(CA IND nX NAM 5)
`(9CI)
`
`[18-[la,2[R*(R*)],3B,5a]]-
`
`IT
`
`RN
`CN
`
`Absolute stereochemistry.
`
`152
`
`0281
`
`0281
`
`

`
`13/308,658
`
`OS.CITING REF COUNT:
`
`3
`
`THnRn ARn 3 CAPLUS RECORDS THAT CITE THIS RECORD
`(3 CITINGS)
`
`ANSWER 81 OF 87
`L49
`ACCESSION NU 3ER:
`DOCJ ENT WJM3ER:
`
`COPYRIGHT 2012 ACS on STN
`HCAPLUS
`l987:59lO2O HCAPLUS
`”
`
`lO7:l9lO2O
`
`ORIGIWAL Rnt«RnNCn NO.:
`TIT.?
`
`107:30449a,30452a
`Method and pharmaceutical composition containing an
`angiotensin-converting enzyme inhibitor for treatment
`of atherosclerosis,
`thrombosis, and peripheral
`Vascu1ar disease.
`
`INVENTOR(S):
`PATENT ASSIGV««(S)
`SOUQCE:
`
`DOCJMENT TYPE:
`LANGUAGE:
`FAMILY ACC. YUM. COUNT:
`PATENT IWFOR.ATION:
`
`Schoe1kens, 3ernward
`Hoechst A.-G., Fed. Rep. Ger.
`Ger. Offen., 10 pp.
`CODEN: GWXXBX
`Patent
`German
`l
`
`?ATENT NO.
`
`KIND
`
`DATE
`
`APPLICATION NO.
`
`DATE
`
`A1
`33 3536687
`A2
`E? 219782
`A3
`E? 219782
`31
`3? 219782
`R:
`AT, 3E, CH, Dn, nS,
`AT 95064
`T
`ES 2059301
`T3
`AU 8663890
`A
`AU 594711
`32
`DK 8604904
`A
`JP 62087524
`A
`ZA 8607771
`A
`CA.1320904
`C
`US 5231080
`A
`PRIORITY APPLN.
`
`INFO.:
`
`19870416
`19870429
`19900530
`19930929
`tR, G3, GR,
`19931015
`19941116
`19870416
`19900315
`19870416
`19870422
`19870527
`19930803
`19930727
`
`33 1985-3536687
`3? 1986-114097
`
`19851015 <—-
`19861011 <——
`
`IT, LI, LU, NL, SE
`AT 1986-114097
`38 1986-114097
`AU 1986-63890
`
`9861011 <——
`9861011 <——
`9861014 <——
`
`DK 1986-4904
`JP 1986-242206
`ZA 1986-7771
`CA.1986-520434
`US 1991-678187
`DE I985-3536687
`-S 1986-917430
`EP 1986-114097
`
`9861014 <——
`9861014 <——
`9861014 <——
`9861014 <——
`9910329 <—-
`_985lOl5 <—-
`A
`31 19861010 <——
`A
`19861011
`
`<__
`
`31 19890811 <——
`-8 1989-393058
`ASSIGNMENT {ISTORY FOR US PATENT AVAILA3L? I\ LSUS DISPLAY FORMAT
`
`OTHER SOURCE(S):
`nD
`«n:ered STN:
`GI
`
`MARPAT lO7:l9lO2O
`27 Nov 1987
`
`153
`
`0282
`
`0282
`
`

`
`13/308,658
`
`H
`
`:3: :N:
`
`IC
`
`H
`
`\CO2H
`
`OCHMeNHCH(CO23t)CH2CH2Ph
`
`II
`
`A3
`
`IT
`
`RN
`
`CN
`
`Angiotensin-converting enzyme inhibitors
`(substituted)
`[n = l,2; R = H,
`R302CCHR4NR5COCHRlNHCH(CO2R2)(CH2)nR (I)
`hydrocarbyl, alkoxy, alkylthio, etc.; R1 = H,
`(substituted) hydrocarbyl,
`(substituted) heteroaryl,
`(protected) amino acid side chain; R2, R3 = H,
`(substituted) hydrocarbyl; R4CHNR5 = C4—l5 heterocyclic mono—, bi—, or
`tricyclic ring system} are inhibitors of blood platelet aggregation and are
`useful for treatment of atherosclerosis, thrombosis, and peripheral Vascular
`disease.
`II, administered orally at l.O-l0.0 mg/kg to rabbits,
`inhibited
`platelet aggregation in vitro and potentiated the action of PGI2. Tablets
`were prepared by mixing II 10 and corn starch 140 with a solution of gelatin
`7.5 g in water, drying, granulating, adding microcryst. cellulose 2.5 and
`Mg stearate 2.5 g, and pressing into tablets each containing 10 mg II.
`Q??%*~§Q~$
`§S?$1«§?~2
`
`RIOL (?iological study)
`(blood olatelet aggregation inhibition by)
`97251-00-8
`HCAPLUS
`
`2—Azabicyclo[3.l.O]heXane—3—carboxylic acid,
`2-[2-[(l-carboxy-3-phenylpropyl)amino]-l-oxoprooyl]-,
`
`[lS—[ld,2[R*(R*)],3B,5d]]— (9CI)
`
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`CO2H
`
`s
`
`s
`
`S
`HO2C
`
`N
`
`\\¢"
`
`o
`
`Ph
`
`3 N//§‘Me
`H
`
`RN
`
`CN
`
`99781-97-2
`
`HCAPLUS
`
`2—Azabicyclo[3.l.O]heXane—3—carboxylic acid,
`2—[2-[[l-(ethoxycarbonyl)-3-phenylpropyl]amino]-l-oXopropyl]—,
`
`[lS—[ld,2[R*(R*)],3B,5d]]-
`
`(9CI)
`
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`154
`
`0283
`
`0283
`
`

`
`13/308,658
`
`OEt
`
`O
`V
`-
`
`CO2H
`
`S
`
`HN/-§-.,———.Ph
`‘::I§;:;ET/’
` MeO
`
`OS.CITING REF COUNT:
`
`7
`
`THnRn ARn 7 CAPLUS RECORDS THAT CITE THIS RECORD
`(7 CITINGS)
`
`ANSWER 82 OF 87
`L49
`ACCESSION WU EER:
`DOCJ ENT WJMEER:
`
`COPYRIGHT 2012 ACS on STN
`HCAPLUS
`
`Fu
`”
`‘
`L987:446283
`HCAPLUS
`
`LO7:46283
`
`ORIGIVAL Rntn%«NC« NO.:
`TIT.?:
`
`INVEWTOR(S):
`
`PATEVT ASSIGVnn(S):
`SOURCI:L‘J
`
`L‘J
`DOCJ ENT TYP :
`LANGJAGE:
`FAMILY ACC. WUM. COUNT:
`PATENT IWFOR.ATION:
`
`107:7613a,7616a
`Treatment of glaucoma using
`angiotensin-convertings-enzyme inhibitors
`Urbach, Hansjoerg; Henning, Rainer; Geiger, Rolf;
`Tee:z, Volker
`Hoechst A.-G., Fed. Rep. Ger.
`Ger. Offen., 31 pp.
`CODEN: GWXXBX
`Patent
`German
`1
`
`?ATENT NO.
`
`KIND
`
`DATE
`
`APPLICATION NO.
`
`DATE
`
`33 3410732
`E3 158157
`
`A1
`A1
`
`19850926
`19851016
`
`33 1984-3410732
`3? 1985-103022
`
`19840323 <—-
`19850315 <—-
`
`19850322 <—-
`19850322 <—-
`
`19850322 <—-
`19850322 <—-
`19840323 <—-
`
`A
`
`155
`
`0284
`
`IT, LI, LU, NL, SE
`AT, 3E, CH, DE, FR, G3,
`R:
`D< 8501315
`A
`19850924
`D< 1985-1315
`AJ 8540288
`A
`19850926
`AJ 1985-40288
`AJ 578079
`32
`19881013
`J? 60209527
`A
`19851022
`ZA.8502156
`A
`19851127
`?RIORITY APPLN.
`OTHER SOURCE(S):
`«D
`«ntered STN:
`GI
`
`INFO.:
`
`MARPAT lO7:46283
`08 Aug 1987
`
`J? 1985-55779
`ZA.1985-2156
`DE 1984-3410732
`
`0284
`
`

`
`13/308,658
`
`The title Compds. R302CCHR4NR5COCHRlNHCH(CO2R2)(CH2)nR.(R.= H, alkyl, aryl,
`R60, R6S, R6 = a'ky , aryl, etc.; R1 = P, alkyl, aryl, amino acyl, etc.; R2,
`R3 = H, alkyl, aryl, etc.; R4CHNR5 = heterocyclyl; n = l, 2) are drugs for
`the treatment of glaucoma.
`Thus,
`tablets were made, containing
`N (l S carb thoxy 3 ph nylpropyl)-S-alanyl-lS,3S,5S-2-
`azabicyclo[3.3.0]octane—3—carboxylic acid 10, corn starch 140, gelatin 7.5,
`microcrystn. ce'lu'ose 2.5, and Mg stearate 2.5 g.
`Q%?31~S?~3
`
`RR: SIOL (Riological study)
`(angiot nsin conv rting nzym inhibitor, as drug for treatment of
`glaucoma)
`9978l—97—2
`
`HCAPLUS
`
`2—Azabicyclo[3.l.O]heXane—3—carboxylic acid,
`2—[2-[[l-(ethoxycarbonyl)-3-phenylpropyl]amino]-l-oXopropyl]—,
`
`[lS—[ld,2[R*(R*)],3B,5d]]— (9CI)
`
`(CA IND«X NAM«)
`
`IT
`
`RN
`CN
`
`Absolute stereochemistry.
`
`O
`\[
`
`OEt
`
`CO2H
`
` ( HN Ph
`
`S
`
`5 Me
`
`O
`
`OS.CITING REF COUNT:
`
`2
`
`THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
`
`(2 CITINGS)
`
`ANSWER 83 OF 87
`L49
`ACCESSION NU SER:
`DOCJ ENT WJMSER:
`
`COPYRIGHT 20l2 ACS on STN
`HCAPLUS
`l986:207685
`HCAPLUS Full-text
`lO4:207685
`
`ORIGIWAL R«t«%«NC« NO
`TIT.?:
`INVEWTOR(S):
`
`l04:32945a,32948a
`Amino acid derivatives as enzyme inhibitors
`Patchett, Arthur A.; Taub, David; Wyvratt, Matthew J.
`Jr.
`
`PATEVT ASSIGN««(S)
`SOUQCE:
`
`Inc., USA
`Merck and Co.,
`S. African,
`81 pp.
`
`156
`
`0285
`
`0285
`
`

`
`13/308,658
`
`DOCJMENT TYPE:
`
`CODEN: SFXXA3
`?atent
`
`LANGUAGE:
`FAMILY ACC. MUM. COUNT:
`PATENT IWFOR.ATION:
`
`English
`1
`
`PATENT NO.
`
`KIND
`
`DATE
`
`APPLICATION NO.
`
`DATE
`
`ZA.8304454
`INFO.:
`?%IORITY APPEN.
`«D
`«ntered STN:
`14 Jun 1986
`
`A
`
`19850227
`
`ZA.1983—4454
`US 1982-389735
`
`19830617 <——
`19820618 <—-
`
`A
`
`GI
`A3
`
`IT
`
`RN
`
`CN
`
`For diagram(s), see printed CA Issue.
`(un)substituted alkyl, aryl,
`Dipeptides I
`(R, R3 = H, alkyl, aryl; R1 = H,
`or heteroaryl, ara1ky1, heteroary1a1ky1; R2 = H, alkyl, aminoalkyl; system
`A is a mono— or bicyc1ic heterocycie), useful as angiotensin—converting
`enzyme inhibitors, were prepared Thus,
`the reductive N—a1ky1ation of an
`a1any1pro1ine derivative with PhCH2CH2COCO2H and Na3H3CN gave dipeptide
`derivative II.
`1S20§§~??~§§
`RL: RCT (Reactant); SPN
`(Reactant or reagent)
`(preparation and reductive alkylation of, by
`102044—77—9
`HCAPLUS
`
`3—Azabicyc1o[3.1.0]hexane—2—carboxy1ic acid,
`
`[1R—[1d,2B,3(S*),5d]]—, mono(trif1uoroacetate
`INDnX NAMn)
`
`3_
`
`)
`
`(2-amino-1-oxopropyl)-,
`(9CI)
`(CA
`
`Et oxophenylbutyrate)
`
`(Synthetic preparation);
`
`PREP
`
`(Preparation);
`
`RACT
`
`157
`
`0286
`
`1 1
`
`01952-31-2
`C9 H14 N2 O3
`
`CM
`
`CRN
`CMF
`
`Absolute stereochemistry.
`
`CM
`
`2
`
`CRN
`CMF
`
`76-O5-1
`C2 H F3 O2
`
`0286
`
`

`
`13/308,658
`
`F— C— CO2H
`
`IT
`
`RN
`
`CN
`
`-.
`\‘
`‘.5
`.-‘zé
`
`
` ..;
`
`
`
`gut.9.). C)C)
`
`
`
`(
`Synthetic preparation);
`PREP (Preparation)
`(preparation of, as angiotensin converting enzyme inhibitor)
`lOl952-28-7
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[2-[(l-carboxy-3-phenylpropyl)amino]-l-oxoprooyl]-,
`(CA IND nX NAM fl)
`(9CI)
`
`[lR-[ld,2B,3[S*(S*)],5a]]-
`
`Absolute stereochemistry.
`
`‘R
`
`HN
`3
`CO2H\\K’/\\\/’
`
`02H
`
`Ph
`
`RN
`
`CN
`
`lOl952-30-l
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[6-amino-2-[(l-carboxy-3-phenylpropyl)amino]-l-oxohexyl]-,
`(CA IND nX NAM fl)
`(9CI)
`
`[lR-[ld,2B,3[S*(R*)],5a]]-
`
`Absolute stereochemistry.
`
`RN
`
`CN
`
`lO2044-73-5
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[2-[(l-carboxy-3-phenylpropyl)amino]-l-oxoprooyl]-,
`(CA IND nX NAM fl)
`(9CI)
`
`[lR-[ld,2B,3[S*(R*)],5a]]-
`
`Absolute stereochemistry.
`
`158
`
`0287
`
`0287
`
`

`
`13/308,658
`
`RN
`CN
`
`l02044—74—6
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-,
`
`[lR—[la,2B,3[S*(S*)],5a]]-
`
`(9CI)
`
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`RN
`CN
`
`l02044—75—7
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-,
`
`[lR—[la,2B,3[S*(R*)],5a]]-
`
`(9CI)
`
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`k
`
`HN\F?X/ Ph
`COZH
`
`O/\ 0:31;
`
`RN
`CN
`
`lO2044—76—8
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[2-[(1-carboxy-3-phenylpropyl)amino]-l-oXopropyl]-
`
`(CA IND nX NAM.
`
`159
`
`0288
`
`0288
`
`

`
`13/308,658
`
`CO2H
`O NH—£H—CH2—CH2—Ph
`E— &H—Me
`
`<q/
`
`CO2H
`
`RN
`
`CN
`
`l02045—l4—7
`
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[6-amino-2-[(1-carboxy-3-phenylpropyl)amino]-1-oxohexyl]-,
`
`[lR—[ld,2B,3[S*(S*)],5d]]-
`
`(9CI)
`
`(CA IND«X NAM«)
`
`Absolute stereochemistry.
`
`IT
`
`iG1«
`
`-3é~5
`
`RN
`
`CN
`
`RL: RCT (Reactant); RACT (Reactant or reagent)
`(reductive alkylation of, by giyoxyiic acid derivative)
`l0l952—34—5
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[2-amino-6-(l,3-dihydro-1,3-dioxo—2H-isoindol-2-yl)-1-oxohexyl]-,
`
`[lR—[ld,2B,3(S*),5d]]—, mono(trifluoroacetate)
`IND«X NAM«)
`
`(9CI)
`
`(CA
`
`CM
`
`1
`
`101952-33-4
`CRN
`CMF C20 H23 N3 05
`
`Absolute stereochemistry.
`
`o
`
`0
`
`(CH2) 4
`
`N”
`
`\ 0
`
`N
`
`s
`
`S
`
`NH2
`HO2C
`
`S
`
`R
`
`160
`
`0289
`
`0289
`
`

`
`161
`
`0290
`
`13/308,658
`
`CM
`
`2
`
`CRN
`CMF
`
`76-O5-l
`C2 H F3 O2
`
`F—£—CO2H
`T
`
`IT
`
`.» w
`9- N. . . Q .»
`:1‘
`wniqqgufiwmm
`
`RN
`
`CN
`
`RL: RCT (Reactant); RACT (Reactant or reagent)
`(reductive amination by, of phenyloxobutyric acid)
`101952-31-2
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid, 3-(2—amino—l—oxopropyl)—,
`
`[lR-[la,2B,3(S*),5a]]-
`
`(9CI)
`
`(CA IND«X NAMn)
`
`Absolute stereochemistry.
`
`IT
`
`1§1§SE~2§~8
`
`RN
`
`CN
`
`RL: RCT (Reactant); RACT (Reactant or reagent)
`(sapoification of)
`l0l952—29—8
`HCAPLUS
`
`3—Azabicyclo[3.l.O]hexane—2—carboxylic acid,
`3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-l-oXopropyl]-
`NAME)
`
`(CA IND
`
`0 Q
`
`-O3t
`O NH—£H—CH2—CH2—Ph
`E-£H——Me
`
`<C“(
`
`CO2H
`
`0290
`
`

`
`13/308,658
`
`L49
`
`ANSWER 84 OF 87
`
`HCAPLUS
`
`COPYRIGHT 2012 ACS on STN
`
`ACCESSION \IU 3'~“.R:
`DOCJ ENT VJM3?R:
`
`1986:39761
`104:39761
`
`HCAPLUS
`
`ORIGIVAL %nt«R«NC« NO
`TIT.3.
`INVE\TOR(S):
`
`PATE\T ASSIGV««(S)
`SOUQCE
`
`DOCJ ENT TYPE:
`LANG-AGE:
`FAMILY ACC. MUM. COUNT:
`PATE\T IVFOR.ATION:
`
`104:6423a,6426a
`Treatment of coronary insufficiency
`Henning, Rainer; Urbach, Hansjoerg; Teetz, Volker;
`Geiger, Rolf; Schoelkens, 3ernward
`Hoechst A.-G., Fed. Rep. Ger.
`Ger. Offen., 27 pp.
`CODEN: GWXXBX
`Patent
`German
`1
`
`?ATENT NO.
`
`KIND
`
`DATE
`
`APPLICATION NO.
`
`DATE
`
`19851024
`A1
`33 3413710
`19851023
`A2
`3? 158927
`19890322
`A3
`3? 158927
`19931208
`31
`3? 158927
`R:
`AT, 3E, CH, DE, FR, G3,
`IT,
`3? 551927
`A1
`19930721
`3? 551927
`31
`19980923
`
`R:
`AT 98128
`AT 171376
`CA.1246457
`AU 8541048
`AU 585502
`JP 60231696
`JP 07045410
`ZA.8502685
`US 5403856
`US 5744496
`US 5684016
`US 5747504
`HK 1012008
`PRIORITY APPLN.
`
`IT,
`AT, 3E, CH, DE, FR, G3,
`T
`19931215
`T
`19981015
`A1
`19881213
`A
`19851017
`32
`19890622
`A
`19851118
`3
`19950517
`A
`19851127
`A
`19950404
`A
`19980428
`A
`19971104
`A
`19980505
`A1
`20000811
`
`INFO.:
`
`33 1984-3413710
`3? 1985-104028
`
`19840412
`19850403
`
`.I,
`
`IL, Nu, SE
`EP 1993-102949
`
`.I,
`
`IL, Nu, SE
`AT 1985-104028
`AT 1993-102949
`CA 1985-478724
`AU 1985-41048
`
`19850403
`
`19850403
`19850403
`19850410
`19850411
`
`JP 1985-75489
`
`19850411
`
`ZA 1985-2685
`US 1994-188745
`US 1994-359860
`US 1995-445543
`US 1996-709286
`H< 1998-113025
`DE 1984-3413710
`EP 1985-104028
`
`19850411
`19940131
`19941220
`19950522
`19960906
`19981209
`19840412
`19850403
`
`A
`A
`
`<__
`
`31 19850410
`US 1985-721705
`31 19890222
`-8 1989-313491
`31 19910103
`-8 1991-636001
`31 19920727
`-8 1992-920173
`A3 19940131
`US 1994-188745
`A3 19941220
`US 1994-359860
`A1 19950522
`-8 1995-445543
`ASSIGNMENT {ISTORY FOR US PATENT AVAILA3LE I\ LSUS DISPLAY FORMAT
`
`OTHER SOURCE(S):
`«D
`«n:ered STN:
`GI
`
`MARPAT lO4:3976l
`08 F

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket